VRDN - Viridian Therapeutics, Inc.\DE
IEX Last Trade
19.71
-0.010 -0.051%
Share volume: 21,000
Last Updated: Thu 26 Dec 2024 08:30:20 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$19.72
-0.01
-0.05%
View ratios
Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
Report Date | 2022-08-15 | 2022-11-14 | 2023-03-09 | 2023-05-10 | 2023-08-08 | 2023-11-13 | 2024-02-27 | 2024-05-08 | |
Total revenue | 256.000 K | 1.195 M | 105.000 K | 98.000 K | 72.000 K | 72.000 K | 72.000 K | 72.000 K | |
Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Gross profit | 256.000 K | 1.195 M | 105.000 K | 98.000 K | 72.000 K | 72.000 K | 72.000 K | 72.000 K | |
366.80% | -91.21% | -6.67% | -26.53% | 0.00% | 0.00% | 0.00% | |||
Operating expenses | 29.820 M | 30.980 M | 49.171 M | 72.571 M | 59.347 M | 51.296 M | 71.550 M | 55.969 M | |
Selling general and admin | 8.108 M | 8.861 M | 9.854 M | 21.831 M | 19.264 M | 20.911 M | 32.993 M | 15.025 M | |
Research and development | 21.712 M | 22.119 M | 39.317 M | 50.740 M | 40.083 M | 30.385 M | 38.557 M | 40.944 M | |
Total expenses | 29.820 M | 30.980 M | 49.171 M | 72.571 M | 59.347 M | 51.296 M | 71.550 M | 55.969 M | |
3.89% | 58.72% | 47.59% | -18.22% | -13.57% | 39.48% | -21.78% | |||
Operating income | -29.564 M | -29.785 M | -49.066 M | -72.473 M | -59.275 M | -51.224 M | -71.478 M | -55.897 M | |
Ebit | -29.564 M | -29.785 M | -49.066 M | -72.473 M | -59.275 M | -51.224 M | -71.478 M | -55.897 M | |
Pretax income | -29.491 M | -28.905 M | -45.785 M | -68.151 M | -55.063 M | -47.660 M | -66.860 M | -48.542 M | |
-1.99% | 58.40% | 48.85% | -19.20% | -13.44% | 40.29% | -27.40% | |||
Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Net income basic | -29.491 M | -28.905 M | -45.785 M | -68.151 M | -55.063 M | -47.660 M | -66.860 M | -48.542 M | |
1.99% | -58.40% | -48.85% | 19.20% | 13.44% | -40.29% | 27.40% | |||
Net income | -29.491 M | -28.905 M | -45.785 M | -68.151 M | -55.063 M | -47.660 M | -66.860 M | -48.542 M | |
1.99% | -58.40% | -48.85% | 19.20% | 13.44% | -40.29% | 27.40% |